B cell immunobiology in disease: Evolving concepts from the clinic

Annual Review of Immunology

Volumn 24, Issue , 2006, Pages 467-496

  Martin, Flavius ^a   Chan, Andrew C ^a  

^a GENENTECH INC   (United States)

Author keywords

BAFF BLyS; BR3; CD20; Rituxan

Indexed keywords

ALEMTUZUMAB; AUTOANTIBODY; B LYMPHOCYTE RECEPTOR; CD16 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD32 ANTIGEN; CD40 ANTIGEN; CD52 ANTIGEN; CD64 ANTIGEN; CHEMOKINE; CHOLINERGIC RECEPTOR; CYTOKINE; EPRATUZUMAB; FC RECEPTOR; RITUXIMAB; THYROTROPIN; THYROTROPIN RECEPTOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANCA ASSOCIATED VASCULITIS; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CRYOGLOBULINEMIA; CYTOKINE PRODUCTION; DENDRITIC CELL; GOODPASTURE SYNDROME; GRAVES DISEASE; HUMAN; IMMUNOBIOLOGY; LYMPHOID TISSUE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; CELL SURVIVAL; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOID TISSUE; MICE; MODELS, IMMUNOLOGICAL; PRIMATES; RECEPTORS, ANTIGEN, B-CELL; T-LYMPHOCYTES;

EID: 33646198040     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.24.021605.090517     Document Type: Review

References (186)

1. Martin F, Chan AC. 2004. Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 20:517-27
2. Silverman GJ, Carson DA. 2003. Roles of B cells in rheumatoid arthritis. Arthritis Res. Ther. 5(Suppl. 4):S1-6
3. Ruff RL, Lennon VA. 1998. End-plate voltage-gated sodium channels are lost in clinical and experimental myasthenia gravis. Ann. Neurol. 43:370-79
4. van Lent PL, Nabbe K, Blom AB, Holthuysen AE, Sloetjes A, et al. 2001. Role of activatory FcγRI and FcγRIII and inhibitory FcγRII in inflammation and cartilage destruction during experimental antigen-induced arthritis. Am. J. Pathol. 159:2309-20
5. Abdul-Majid KB, Stefferl A, Bourquin C, Lassmann H, Linington C, et al. 2002. Fc receptors are critical for autoimmune inflammatory damage to the central nervous system in experimental autoimmune encephalomyelitis. Scand. J. Immunol. 55:70-81
6. Fujii T, Hamano Y, Ueda S, Akikusa B, Yamasaki S, et al. 2003. Predominant role of FcγRIII in the induction of accelerated nephrotoxic glomerulonephritis. Kidney Int. 64:1406-16
7. Pritchard NR, Cutler AJ, Uribe S, Chadban SJ, Morley BJ, Smith KG. 2000. Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcγRII. Curr. Biol. 10:227-30
8. Bolland S, Ravetch JV. 2000. Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity 13:277-85
9. McGaha TL, Sorrentino B, Ravetch JV. 2005. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307:590-93
10. Jiang Y, Hirose S, Abe M, Sanokawa-Akakura R, Ohtsuji M, et al. 2000. Polymorphisms in IgG Fc receptor IIB regulatory regions associated with autoimmune susceptibility. Immunogenetics 51:429-35
11. Jiang Y, Hirose S, Sanokawa-Akakura R, Abe M, Mi X, et al. 1999. Genetically determined aberrant down-regulation of FcγRIIB1 in germinal center B cells associated with hyper-IgG and IgG autoantibodies in murine systemic lupus erythematosus. Int. Immunol. 11:1685-91
12. Xiu Y, Nakamura K, Abe M, Li N, Wen XS, et al. 2002. Transcriptional regulation of FcγR2b gene by polymorphic promoter region and its contribution to humoral immune responses. J. Immunol. 169:4340-46
13. Boule MW, Broughton C, MacKay F, Akira S, Marshak-Rothstein A, Rifkin IR. 2004. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 199:1631-40
14. Vallin H, Perers A, Alm GV, Ronnblom L. 1999. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus. J. Immunol. 163:6306-13
15. Bave U, Magnusson M, Eloranta ML, Perers A, Aim GV, Ronnblom L. 2003. FcγRIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG. J. Immunol. 171:3296-302
16. Harris J, Vaughan JH. 1961. Transfusion studies in rheumatoid arthritis. Arthritis Rheum. 4:47-55
17. Kallies A, Hasbold J, Tarlinton DM, Dietrich W, Corcoran LM, et al. 2004. Plasma cell ontogeny defined by quantitative changes in Blimp-1 expression. J. Exp. Med. 200:967-77
18. Dorner T, Radbruch A. 2005. Selecting B cells and plasma cells to memory. J. Exp. Med, 201:497-99
19. Odendahl M, Mei H, Hoyer BF, Jacobi AM, Hansen A, et al. 2005. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 105:1614-21
20. Blink EJ, Light A, Kallies A, Nutt SL, Hodgkin PD, Tarlinton DM. 2005. Early appearance of germinal center-derived memory B cells and plasma cells in blood after primary immunization. J. Exp. Med. 201:545-54
21. William J, Euler C, Christensen S, Shlomchik MJ. 2002. Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science 297:2066-70
22. Shlomchik MJ, Marshak-Rothstein A, Wolfowicz CB, Rothstein TL, Weigert MG. 1987. The role of clonal selection and somatic mutation in autoimmunity. Nature 328:805-11
23. Shlomchik M, Mascelli M, Shan H, Radic MZ, Pisetsky D, et al. 1990. Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. J. Exp. Med. 171:265-92
24. Shlomchik MJ, Euler CW, Christensen SC, William J. 2003. Activation of rheumatoid factor (RF) B cells and somatic hypermutation outside of germinal centers in autoimmune-prone MRL/lpr mice. Ann. NY Acad. Sci. 987:38-50
25. Dorner T, Egerer K, Feist E, Burmester GR. 2004. Rheumatoid factor revisited. Curr. Opin. Rheumatol. 16:246-53
26. William J, Euler C, Shlomchik MJ. 2005. Short-lived plasmablasts dominate the early spontaneous rheumatoid factor response: differentiation pathways, hypermutating cell types, and affinity maturation outside the germinal center. J. Immunol. 174:6879-87
27. Shlomchik MJ, Madaio MP, Ni D, Trounstein M, Huszar D. 1994. The role of B cells in lpr/lpr-induced autoimmunity. J. Exp. Med. 180:1295-306
28. Chan O, Shlomchik MJ. 1998. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J. Immunol. 160:51-59
29. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. 1999. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189:1639-48
30. Wong FS, Wen L, Tang M, Ramanathan M, Visintin I, et al. 2004. Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. Diabetes 53:2581-87
31. Wellmann U, Letz M, Schneider A, Amann K, Winkler TH. 2001. An Ig μ-heavy chain transgene inhibits systemic lupus erythematosus immunopathology in autoimmune (NZB × NZW)F1 mice. Int. Immunol. 13:1461-69
32. Chan OT, Madaio MP, Shlomchik MJ. 1999. B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J. Immunol 163:3592-96
33. + T cell activation in MRL-Fas(lpr) mice independently of MHC class I antigen presentation. J. Immunol. 164:1658-62
34. O'Neill SK, Shlomchik MJ, Giant TT, Cao Y, Doodes PD, Finnegan A. 2005. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J. Immunol. 174:3781-88
35. Kalled SL, Cutler AH, Datta SK, Thomas DW. 1998. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J. Immunol. 160:2158-65
36. De Jong YP, Comiskey M, Kalled SL, Mizoguchi E, Flavell RA, et al. 2000. Chronic murine colitis is dependent on the CD154/CD40 pathway and can be attenuated by anti-CD154 administration. Gastroenterology 119:715-23
37. Kaser A, Dunzendorfer S, Offner FA, Ludwiczek O, Enrich B, et al. 2000. B lymphocyte-derived IL-16 attracts dendritic cells and Th cells. J. Immunol. 165:2474-80
38. Krzysiek R, Lefevre EA, Zou W, Foussat A, Bernard J, et al. 1999. Antigen receptor engagement selectively induces macrophage inflammatory protein-1α (MIP-1α) and MIP-1β chemokine production in human B cells. J. Immunol. 162:4455-63
39. Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, Moser M. 2000. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J. Exp. Med. 192:475-82
40. Fu YX, Huang G, Matsumoto M, Molina H, Chaplin DD. 1997. Independent signals regulate development of primary and secondary follicle structure in spleen and mesenteric lymph node. Proc. Natl. Acad. Sci. USA 94:5739-43
41. Ansel KM, Cyster JG. 2001. Chemokines in lymphopoiesis and lymphoid organ development. Curr. Opin. Immunol. 13:172-79
42. Ansel KM, Ngo VN, Hyman PL, Luther SA, Forster R, et al. 2000. A chemokine-driven positive feedback loop organizes lymphoid follicles Nature 406:309-14
43. Cyster JG, Ngo VN, Ekland EH, Gunn MD, Sedgwick JD, Ansel KM. 1999. Chemokines and B-cell homing to follicles. Curr. Top. Microbiol. Immunol. 246:87-92
44. Weyand CM, Kang YM, Kurtin PJ, Goronzy JJ. 2003. The power of the third dimension: tissue architecture and autoimmunity in rheumatoid arthritis. Curr. Opin. Rheumatol. 15:259-66
45. Corcione A, Casazza S, Ferretti E, Giunti D, Zappia E, et al. 2004. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc. Natl. Acad. Sci. USA 101:11064-69
46. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. 2004. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 14:164-74
47. Uccelli A, Aloisi F, Pistoia V. 2005. Unveiling the enigma of the CNS as a B-cell fostering environment. Trends Immunol. 26:254-59
48. Barone F, Bombardieri M, Manzo A, Blades MC, Morgan PR, et al. 2005. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren's syndrome. Arthritis Rheum. 52:1773-84
49. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, et al. 2002. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J. Clin. Invest. 109:59-68
50. + T and CCR7 B and T lymphocytes in thyroid autoimmune diseases. J. Immunol. 170:6320-28
51. Weyand CM, Kurtin PJ, Goronzy JJ. 2001. Ectopic lymphoid organogenesis: a fast track for autoimmunity. Am. J. Pathol. 159:787-93
52. Aust G, Sittig D, Becherer L, Anderegg U, Schutz A, et al. 2004. The role of CXCR5 and its ligand CXCLl 3 in the compartmentalization of lymphocytes in thyroids affected by autoimmune thyroid diseases. Eur. J. Endocrinol. 150:225-34
53. Peterson KS, Huang JF, Zhu J, D'Agati V, Liu X, et al. 2004. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J. Clin. Invest. 113:1722-33
54. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. 2001. T cell activation in rheumatoid synovium is B cell dependent. J. Immunol. 167:4710-18
55. Cooper MD, Kearney JF, Gainings WE, Lawton AR. 1980. Effects of anti-Ig antibodies on the development and differentiation of B cells. Immunol. Rev. 52:29-53
56. Chentoufi AA, Nizet Y, Havaux X, De La Parra B, Cormont F, et al. 1999. Differential effects of injections of anti-μ and anti-δ monoclonal antibodies on B-cell populations in adult mice: regulation of xenoreactive natural antibody-producing cells. Transplantation 68:1728-36
57. Chentoufi AA, Nizet Y, Havaux X, Nisol F, Bazin H, Latinne D. 2000. B-cell suppression in adult mice injected with anti-δ followed by anti-μ mAb. Cell. Immunol. 205:40-51
58. Finkelman FD, Holmes JM, Dukhanina OI, Morris SC. 1995. Cross-linking of membrane immunoglobulin D, in the absence of T cell help, kills mature B cells in vivo. J. Exp. Med. 181:515-25
59. Cerny A, Starobinski M, Hugin AW, Sutter S, Zinkernagel RM, Izui S. 1987. Treatment with high doses of anti-IgM prevents, but with lower doses accelerates autoimmune disease in (NZW × BXSB)F1 hybrid mice. J. Immunol. 138:4222-28
60. Cerny A, Sutter S, Bazin H, Hengartner H, Zinkernagel RM. 1988. Clearance of lymphocytic choriomeningitis virus in antibody- and B-cell-deprived mice. J. Virol. 62:1803-7
61. Cheever AW, Byram JE, Hieny S, von LF, Lunde MN, Sher A. 1985. Immunopathology of Schistosoma japonicum and S. mansoni infection in B cell depleted mice. Parasite Immunol. 7:399-413
62. Koyama M, Ishihara K, Karasuyama H, Cordell JL, Iwamoto A, Nakamura T. 1997. CD79α/CD79β heterodimers are expressed on pro-B cell surfaces without associated μ heavy chain. Int. Immunol. 9:1767-72
63. Nagata K, Nakamura T, Kitamura F, Kuramochi S, Taki S, et al. 1997. The Igα/Igβ heterodimer on μ-negative proB cells is competent for transducing signals to induce early B cell differentiation. Immunity 7:559-70
64. Zhang L, French RR, Chan HT, O'Keefe TL, Cragg MS, et al. 1995. The development of anti-CD79 monoclonal antibodies for treatment of B-cell neoplastic disease. Ther. Immunol. 2:191-202
65. Riley JK, Sliwkowski MX. 2000. CD20: a gene in search of a function. Semin. Oncol. 27:17-24
66. Uchida J, Lee Y, Hasegawa M, Liang Y, Bradney A, et al. 2004. Mouse CD20 expression and function. Int. Immunol. 16:119-29
67. Clynes RA, Towers TL, Presta LG, Ravetch JV. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6:443-46
68. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, et al. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199:1659-69
69. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, et al. 2005. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174:817-26
70. Hamaguchi Y, Uchida J, Cain DW, Venturi GM, Poe JC, et al. 2005. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J. Immunol. 174:4389-99
71. Flynn JM, Byrd JC. 2000. Campath-1H monoclonal antibody therapy. Curr. Opin. Oncol. 12:574-81
72. Robak T. 2005. Alemtuzumab in the treatment of chronic lymphocytic leukemia. Bio-Drugs 19:9-22
73. Dullforce P, Sutton DC, Heath AW. 1998. Enhancement of T cell-independent immune responses in vivo by CD40 antibodies. Nat. Med. 4:88-91
74. Pearson TC, Trambley J, Odom K, Anderson DC, Cowan S, et al. 2002. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 74:933-40
75. Dunussi-Joannopoulos K, Hancock GE, Kunz A, Hegen M, Zhou XX, et al. 2005. B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model. Blood 106:2235-43
76. Waldor MK, Hardy RR, Hayakawa K, Steinman L, Herzenberg LA, Herzenberg LA. 1984. Disappearance and reappearance of B cells after in vivo treatment with monoclonal anti-I-A antibodies. Proc. Natl. Acad. Sci. USA 81:2855-58
77. Vladutiu AO, Steinman L. 1987. Inhibition of experimental autoimmune thyroiditis in mice by anti-I-A antibodies. Cell. Immunol. 109:169-80
78. Grabstein KH, Waldschmidt TJ, Finkelman FD, Hess BW, Alpert AR, et al. 1993. Inhibition of murine B and T lymphopoiesis in vivo by an anti-interleukin 7 monoclonal antibody. J. Exp. Med. 178:257-64
79. Giliani S, Mori L, de Saint BG, Le DF, Rodriguez-Perez C, et al. 2005. Interleukin-7 receptor α (IL-7Rα) deficiency: cellular and molecular bases. Analysis of clinical, immunological, and molecular features in 16 novel patients. Immunol. Rev. 203:110-26
80. Dahlenborg K, Pound JD, Gordon J, Borrebaeck CA, Carlsson R. 2000. Signals sustaining human immunoglobulin V gene hypermutation in isolated germinal centre B cells. Immunology 101:210-17
81. Pound JD, Gordon J. 1997. Maintenance of human germinal center B cells in vitro. Blood 89:919-28
82. Liu YJ, Banchereau J. 1997. Regulation of B-cell commitment to plasma cells or to memory B cells. Semin. Immunol. 9:235-40
83. Mehta DS, Wurster AL, Grusby MJ. 2004. Biology of IL-21 and the IL-21 receptor. Immunol. Rev. 202:84-95
84. Chtanova T, Tangye SG, Newton R, Frank N, Hodge MR, et al. 2004. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J. Immunol. 173:68-78
85. Vinuesa CG, Cook MC, Angelucci C, Athanasopoulos V, Rui L, et al. 2005. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 435:452-58
86. Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, et al. 2004. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J. Immunol. 173:5361-71
87. Jin H, Carrio R, Yu A, Malek TR. 2004. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J. Immunol. 173:657-65
88. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683-765
89. Asadullah K, Sterry W, Volk HD. 2003. Interleukin-10 therapy-review of a new approach. Pharmacol. Rev. 55:241-69
90. Asadullah K, Sabat R, Friedrich M, Volk HD, Sterry W. 2004. Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis. Curr. Drug Targets Inflamm. Allergy 3:185-92
91. Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed SG, Maliszewski CR. 1996. CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 4:283-89
92. De Jong YP, Comiskey M, Kalled SL, Mizoguchi E, Flavell RA, et al. 2000. Chronic murine colitis is dependent on the CD154/CD40 pathway and can be attenuated by anti-CD154 administration. Gastroenterology 119:715-23
93. Grewal IS, Foellmer HG, Grewal KD, Xu J, Hardardottir F, et al. 1996. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 273:1864-67
94. Kalled SL, Cutler AH, Ferrant JL. 2001. Long-term anti-CD154 dosing in nephritic mice is required to maintain survival and inhibit mediators of renal fibrosis. Lupus 10:9-22
95. Sidiropoulos PI, Boumpas DT. 2004. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13:391-97
96. Grammer AC, Slota R, Fischer R, Gur H, Girschick H, et al. 2003. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J. Clin. Invest. 112:1506-20
97. Ferrant JL, Benjamin CD, Cutler AH, Kalled SL, Hsu YM, et al. 2004. The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. Int. Immunol. 16:1583-94
98. + T cell functions. J. Exp. Med. 183:2209-18
99. Aruffo A, Hollenbaugh D, Wu LH, Ochs HD. 1994. The molecular basis of X-linked agammaglobulinemia, hyper-IgM syndrome, and severe combined immunodeficiency in humans. Curr. Opin. Hematol. 1:12-18
100. Kalled SL. 2005. The role of BAFF in immune function and implications for autoimmunity. Immunol. Rev. 204:43-54
101. MacKay F, Schneider P, Rennert P, Browning J. 2003. BAFF and APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21:231-64
102. Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, et al. 2004. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20:441-53
103. Xu LG, Wu M, Hu J, Zhai Z, Shu HB. 2002. Identification of downstream genes upregulated by the tumor necrosis factor family member TALL-1. J. Leukoc. Biol. 72:410-16
104. Kayagaki N, Yan M, Seshasayee D, Wang H, Lee W, et al. 2002. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2. Immunity 17:515-24
105. Claudio E, Brown K, Park S, Wang H, Siebenlist U. 2002. BAFF-induced NEMO-independent processing of NF-κB2 in maturing B cells. Nat. Immunol. 3:958-65
106. Vora KA, Wang LC, Rao SP, Liu ZY, Majeau GR, et al. 2003. Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J. Immunol. 171:547-51
107. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, et al. 2001. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293:2111-14
108. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, et al. 2004. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20:785-98
109. MacKay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, et al. 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190:1697-710
110. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, et al. 2000. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404:995-99
111. Khare SD, Sarosi I, Xia XZ, McCabe S, Miner K, et al. 2000. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc. Natl. Acad. Sci. USA 97:3370-75
112. Ramanujam M, Wang X, Huang W, Schiffer L, Grimaldi C, et al. 2004. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J. Immunol. 173:3524-34
113. Liu W, Szalai A, Zhao L, Liu D, Martin F, et al. 2004. Control of spontaneous B lymphocyte autoimmutiity with adenovirus-encoded soluble TACI. Arthritis Rheum. 50:1884-96
114. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, et al. 2003. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 48:3475-86
115. Reff ME, Garner K, Chambers KS, Chinn PC, Leonard JE, et al. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-45
116. Vugmeyster Y, Beyer J, Howell K, Combs D, Fielder P, et al. 2005. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J. Immunother. 28:212-19
117. Vugmeyster Y, Howell K, McKeever K, Combs D, Canova-Davis E. 2003. Differential in vivo effects of Rituximab on two B-cell subsets in cynomolgus monkeys. Int. Immunopbarmacol. 3:1477-81
118. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, et al. 2003. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48:3253-65
119. Martin F, Kearney JF. 2002. Marginal-zone B cells. Nat. Rev. Immunol. 2:323-35
120. Rastetter W, Molina A, White CA, 2004. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu. Rev. Med. 55:477-503
121. Avivi I, Robinson S, Goldstone A. 2003. Clinical use of Rituximab in haematological malignancies. Br. J. Cancer 89:1389-94
122. Silberstein LE. 1994. B-cell origin of cold agglutinins. Adv. Exp. Med. Biol. 347:193-205
123. Pascual M, Mach-Pascual S, Schifferli JA. 1997. Paraproteins and complement depletion: pathogenesis and clinical syndromes. Semin. Hematol. 34:40-48
124. Ward JH. 2001. Autoimmunity in chronic lymphocytic leukemia. Curr. Treat. Options Oncol. 2:253-57
125. Lee EJ, Kueck B. 1998. Rituxan in the treatment of cold agglutirun disease. Blood 92:3490-91
126. Schiller G, Tillisch J, Rosen P. 1999. Use of anti-CD20 monoclonal antibody for the treatment of Evans syndrome and monoclonal gammopathy/ neuropathy syndrome. Blood 94:84B (Abstr.)
127. Zaja F, Russo D, Fuga G, Patriarca F, Ermacora A, Baccarani M. 1999. Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica 84:1157-58
128. Treon SP, Anderson KC. 2000. The use of Rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin. Oncol. 27:79-85
129. Robak T. 2004. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur. J. Haematol. 72:79-88
130. Raj A, Bertolone S, Cheerva A. 2004. Successful treatment of refractory autoimmune hemolytic anemia with monthly Rituximab following nonmyeloablative stem cell transplantation for sickle cell disease. J. Pediatr. Hematol. Oncol. 26:312-14
131. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, et al. 2003. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101:3857-61
132. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, et al. 2001. Treatment of childhood autoimmune haemolytic anaemia with Rituximab. Lancet 358:1511-13
133. Saleh MN, Gutheil J, Moore M, Bunch PW, Butler J, et al. 2000. A pilot study of the anti-CD20 monoclonal antibody Rituximab in patients with refractory immune thrombocytopenia. Semin. Oncol. 27:99-103
134. Stasi R, Pagano A, Stipa E, Amadori S. 2001. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98:952-57
135. Zaja F, Vianelli N, Sperotto A, De Vita S, Iacona I, et al. 2003. B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 88:538-46
136. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, et al. 2004, The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br. J. Haematol. 125:232-39
137. Samuelsson A, Towers TL, Ravetch JV. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484-86
138. Levine TD, Pestronk A. 1999. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 52:1701-4
139. Pestronk A, Florence J, Miller T, Choksi R, Al Lozi MT, Levine TD. 2003. Treatment of IgM antibody associated polyneuropathies using Rituximab. J. Neurol. Neurosurg. Psychiatry 74:485-89
140. Rojas-Garcia R, Gallardo E, de Andres I, de Luna N, Juarez C, etal. 2003. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to Rituximab. Neurology 61:1814-16
141. Renaud S, Gregor M, Fuhr P, Lorenz D, Deuschl G, et al. 2003. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27:611-15
142. Nobile-Orazio E. 2004. IgM paraproteinaemic neuropathies. Curr. Opin. Neurol. 17:599-605
143. Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, et al. 2002. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 100:3426-28
144. Keogh KA, Wylam ME, Stone JH, Specks U. 2005. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52:262-68
145. Eriksson P. 2005. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with Rituximab. J. Intern. Med. 257:540-48
146. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, deJong PE, Kallenberg CG. 1994. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann. Intern. Med. 120:12-17
147. Shaw T, Quan J, Totoritis MC. 2003. B cell therapy for rheumatoid arthritis: the Rituximab (anti-CD20) experience. Ann. Rheum. Dis. 62(Suppl. 2):ii55-59
148. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emory P, et al. 2004. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350:2572-81
149. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, et al. 2003. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48:2146-54
150. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G. 2002. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 46:2029-33
151. Tuscano JM. 2002. Successful treatment of infliximab-refractory rheumatoid arthritis with Rituximab. Arthritis Rheum. 46:3420
152. Weyand CM, Goronzy JJ. 2003. Ectopic germinal center formation in rheumatoid synovitis. Ann. NY Acad. Sci. 987:140-49
153. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. 2002. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46:2673-77
154. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, et al. 2003. The relationship of FcγRIIIa genotype to degree of B cell depletion by Rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48:455-59
155. Eisenberg R. 2003. Mechanisms of autoimmunity. Immunol. Res. 27:203-18
156. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, et al. 2004. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of Rituximab. Arthritis Rheum. 50:2580-89
157. Tomietto P, Gremese E, Tolusso B, Venturini P, De VS, Ferraccioli G. 2004. B cell depletion may lead to normalization of anti-platelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus. Thromb. Haemost. 92:1150-53
158. Reiff A. 2005. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology 10:79-93
159. Isaacs JD, Manna VK, Rapson N, Bulpitt KJ, Hazleman BL, et al 1996. CAMPATH-1H in rheumatoid arthritis-an intravenous dose-ranging study. Br. J. Rheumatol. 35:231-40
160. Weinblatt ME, Maddison PJ, Bulpitt KJ, Hazleman BL, Urowitz MB, et al. 1995. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum. 38:1589-94
161. Coles AJ, Wing M, Smith S, Coraddu F, Greer S, et al. 1999. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354:1691-95
162. Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, et al. 2001. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br. J. Haematol. 114:891-98
163. Marsh JC, Gordon-Smith EC. 2001. CAMPATH-1H in the treatment of autoimmune cytopenias. Cytotherapy 3:189-95
164. Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, et al. 2003. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 21:3051-59
165. Juweid M. 2003. Technology evaluation: epratuzumab, Immunomedics/Amgen. Curr. Opin. Mol. Ther. 5:192-98
166. Huang W, Sinha J, Newman J, Reddy B, Budhai L, et al. 2002. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum. 46:1554-62
167. Grammer AC, Lipsky PE. 2002. CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum. 46:1417-29
168. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, et al. 2003. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann. Rheum. Dis. 62:168-71
169. Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette X. 2004. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J. Pathol. 202:496-502
170. Hamaguchi Y, Uchida J, Cain DW, Venturi GM, Poe JC, et al. 2005. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J. Immunol. 174:4389-99
171. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. 2005. The biology of CD20 and its potential as a target for niAb therapy. Curr. Dir. Autoimmun. 8:140-74
172. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, etal. 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104:1793-800
173. Stanglmaier M, Reis S, Hallek M. 2004. Rituximab and alemtuzumab induce a non-classic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann. Hematol. 83:634-45
174. Jazirehi AR, Bonavida B. 2005. Cellular and molecular signal transduction pathways modulated by Rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24:2121-43
175. Harjunpaa A, Junnikkala S, Meri S. 2000. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand. J. Immunol. 51:634-41
176. Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, et al. 2002. Binding to CD20 by anti-B1 antibody or F(ab′)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol. Immunother. 51:15-24
177. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, et al. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcrγRIIIa gene. Blood 99:754-58
178. Weng WK, Levy R. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to Rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21:3940-47
179. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, et al. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277:26733-40
180. Friedberg JW, Neuberg D, Gribben JG, Fisher DC, Canning C, et al. 2002. Combination immunotherapy with Rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br. J. Haematol. 117:828-34
181. Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, et al. 2004. Phase I studies of interleukin (IL)-2 and Rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin. Cancer Res. 10:2253-64
182. Olivieri A, Lucesole M, Capelli D, Gini G, Montanari M, et al. 2005. A new schedule of CHOP/Rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. Biol. Blood Marrow Transplant. 11:627-36
183. Niitsu N, Hayama M, Okamoto M, Khori M, Higashihara M, et al. 2004. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma. Clin. Cancer Res. 10:4077-82
184. Mori Y, Shimizu N, Dallas M, Niewolna M, Story B, et al. 2004. Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104:2149-54
185. Huang YW, Richardson JA, Vitetta ES. 1995. Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells. Cancer Res. 55:610-16
186. Olson DL, Burkly LC, Leone DR, Dolinski BM, Lobb RR. 2005. Anti-α4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Mol. Cancer Ther. 4:91-99